Search

Your search keyword '"Ara, Takahide"' showing total 8 results
Start Over Author "Ara, Takahide" Publisher wiley
8 results on '"Ara, Takahide"'

1. Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era

Author

Ishida, Hisashi, primary, Shimada, Hiroyuki, additional, Tanizawa, Akihiko, additional, Shimazu, Yutaka, additional, Tachibana, Takayoshi, additional, Doki, Noriko, additional, Ara, Takahide, additional, Matsuo, Yayoi, additional, Nara, Miho, additional, Toubai, Tomomi, additional, Ino, Kazuko, additional, Nakamae, Hirohisa, additional, Kato, Keisuke, additional, Kato, Koji, additional, Sato, Atsushi, additional, Hino, Moeko, additional, Matsumoto, Kimikazu, additional, Atsuta, Yoshiko, additional, Yasui, Masahiro, additional, and Nagamura‐Inoue, Tokiko, additional

Published
2023
Full Text
View/download PDF

2. Prognostic impact of complex and/or monosomal karyotypes in post‐transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach

Author

10826564, Jo, Tomoyasu, Arai, Yasuyuki, Oshima, Shinichiro, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Kuriyama, Takuro, Ikegame, Kazuhiro, Katayama, Yuta, Ota, Shuichi, Ara, Takahide, Kawakita, Toshiro, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, Yanada, Masamitsu, 10826564, Jo, Tomoyasu, Arai, Yasuyuki, Oshima, Shinichiro, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Kuriyama, Takuro, Ikegame, Kazuhiro, Katayama, Yuta, Ota, Shuichi, Ara, Takahide, Kawakita, Toshiro, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu

Abstract

To evaluate the prognostic impact of complex karyotype (CK) and/or monosomal karyotype (MK) in combination with various clinical factors on allogeneic stem cell transplantation (HSCT) outcomes of patients with acute myeloid leukaemia (AML), we analysed the registry database of adult AML patients who underwent allogeneic HSCT between 2000 and 2019 in Japan. Among 16 094 patients, those with poor cytogenetic risk (N = 3345) showed poor overall survival (OS) after HSCT (25.3% at 5 years). Multivariate analyses revealed that CK and/or MK (hazard ratio [HR], 1.31 for CK without MK; 1.27 for MK without CK; and 1.73 for both), age at HSCT ≥50 years (HR, 1.58), male sex (HR, 1.40), performance status ≥2 (HR, 1.89), HCT-CI score ≥3 (HR, 1.23), non-remission status at HSCT (HR, 2.49), and time from diagnosis to HSCT ≥3 months (HR, 1.24) independently reduced post-HSCT OS among patients with poor cytogenetic risk AML. A risk scoring system based on the multivariate analysis successfully stratified patients into five distinct groups for OS. This study confirms the negative effects of CK and MK on post-HSCT outcomes, and offers a powerful risk scoring system for predicting prognoses after HSCT among AML patients with unfavourable cytogenetics.

Published
2023

3. Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan

Author

Konuma, Takaaki, primary, Itonaga, Hidehiro, additional, Ishiyama, Ken, additional, Hamamura, Atsushi, additional, Uchida, Naoyuki, additional, Ozawa, Yukiyasu, additional, Katayama, Yuta, additional, Sakurai, Masatoshi, additional, Ueda, Yasunori, additional, Matsuoka, Ken‐ichi, additional, Kawakita, Toshiro, additional, Eto, Tetsuya, additional, Ara, Takahide, additional, Kanda, Junya, additional, Onizuka, Makoto, additional, Fukuda, Takahiro, additional, and Atsuta, Yoshiko, additional

Published
2023
Full Text
View/download PDF

4. Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group

Author

Yanagisawa, Ryu, primary, Tamaki, Masaharu, additional, Tanoshima, Reo, additional, Misaki, Yukiko, additional, Uchida, Naoyuki, additional, Koi, Satoshi, additional, Tanaka, Takashi, additional, Ozawa, Yukiyasu, additional, Matsuo, Yayoi, additional, Tanaka, Masatsugu, additional, Ikegame, Kazuhiro, additional, Katayama, Yuta, additional, Matsuoka, Ken‐ichi, additional, Ara, Takahide, additional, Kanda, Yoshinobu, additional, Matsumoto, Kimikazu, additional, Fukuda, Takahiro, additional, Atsuta, Yoshiko, additional, Kato, Motohiro, additional, and Nakasone, Hideki, additional

Published
2022
Full Text
View/download PDF

5. Haploidentical transplantation with post‐transplant cyclophosphamide versus single cord blood transplantation for myelodysplastic syndrome: A retrospective study from the Adult Myelodysplastic Syndrome Working Group of the Japanese Society for Transplantation and Cellular Therapy ( JSTCT )

Author

Konuma, Takaaki, primary, Shimomura, Yoshimitsu, additional, Ishiyama, Ken, additional, Ara, Takahide, additional, Nakamae, Hirohisa, additional, Hiramoto, Nobuhiro, additional, Eto, Tetsuya, additional, Maruyama, Yumiko, additional, Nagafuji, Koji, additional, Ishikawa, Jun, additional, Uchida, Naoyuki, additional, Tanaka, Masatsugu, additional, Onizuka, Makoto, additional, Ueda, Yasunori, additional, Anzai, Naoyuki, additional, Kimura, Takafumi, additional, Kanda, Yoshinobu, additional, Fukuda, Takahiro, additional, and Atsuta, Yoshiko, additional

Published
2022
Full Text
View/download PDF

6. Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI

Author

Morita‐Fujita, Mari, primary, Arai, Yasuyuki, additional, Kondo, Tadakazu, additional, Harada, Kaito, additional, Uchida, Naoyuki, additional, Toya, Takashi, additional, Ozawa, Yukiyasu, additional, Fukuda, Takahiro, additional, Ota, Shuichi, additional, Onizuka, Makoto, additional, Kanda, Yoshinobu, additional, Maruyama, Yumiko, additional, Takada, Satoru, additional, Kawakita, Toshiro, additional, Ara, Takahide, additional, Ichinohe, Tatsuo, additional, Kimura, Takafumi, additional, Atsuta, Yoshiko, additional, and Kako, Shinichi, additional

Published
2022
Full Text
View/download PDF

7. Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI

Author

10826564, Morita-Fujita, Mari, Arai, Yasuyuki, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Toya, Takashi, Ozawa, Yukiyasu, Fukuda, Takahiro, Ota, Shuichi, Onizuka, Makoto, Kanda, Yoshinobu, Maruyama, Yumiko, Takada, Satoru, Kawakita, Toshiro, Ara, Takahide, Ichinohe, Tatsuo, Kimura, Takafumi, Atsuta, Yoshiko, Kako, Shinichi, 10826564, Morita-Fujita, Mari, Arai, Yasuyuki, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Toya, Takashi, Ozawa, Yukiyasu, Fukuda, Takahiro, Ota, Shuichi, Onizuka, Makoto, Kanda, Yoshinobu, Maruyama, Yumiko, Takada, Satoru, Kawakita, Toshiro, Ara, Takahide, Ichinohe, Tatsuo, Kimura, Takafumi, Atsuta, Yoshiko, and Kako, Shinichi

Abstract

The medium-dose etoposide (VP16) added on cyclophosphamide (CY)/total body irradiation (TBI) is one of the intensified myeloablative conditioning regimens used in allogenic hematopoietic stem cell transplantation (allo-HSCT) for acute lymphoblastic leukemia (ALL). However, the patient subgroups who can actually benefit from VP16/CY/TBI compared to CY/TBI have not been precisely defined. Therefore, we conducted a multi-center retrospective study using the Japanese nationwide registry database to elucidate the efficacy of VP16/CY/TBI on post-transplant prognosis. Biological and clinical distinct subtypes (i.e., Philadelphia chromosome-positive (Ph+) and -negative (Ph−) ALL) were evaluated separately, which included 820 Ph+ and 1463 patients with Ph− ALL, respectively. Compared with the CY/TBI group, the VP16/CY/TBI group showed superior progression-free survival (PFS) in patients with Ph+ ALL (65% vs. 57% at 3 years after HSCT; adjusted hazard ratio (HR), 0.73; 95% confidence interval (CI), 0.55–0.98; p = 0.03), along with significantly reduced incidence of relapse (adjusted HR, 0.58; 95% CI, 0.37–0.90; p = 0.02) without the increase of non-relapse mortality (NRM). By contrast, in patients with Ph− ALL, VP16/CY/TBI did not improve PFS nor incidence of relapse; addition of VP16 reduced relapse (HR, 0.65; p = 0.06) in patients with Ph− ALL transplanted at CR1, while improved PFS was not observed (HR, 0.90; p = 0.52) due to increased NRM. This study demonstrated that VP16/CY/TBI is a more effective and well-tolerated regimen in comparison with CY/TBI in patients with myeloablative allo-HSCT for adult Ph+ ALL. Our findings can provide a novel algorithm for conditioning regimen selection in patients with adult ALL.

Published
2022

8. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan

Author

Yamamoto, Masahide, primary, Sato, Maho, additional, Onishi, Yasushi, additional, Sasahara, Yoji, additional, Sano, Hideki, additional, Masuko, Masayoshi, additional, Nakamae, Hirohisa, additional, Matsuoka, Ken‐ichi, additional, Ara, Takahide, additional, Washio, Kana, additional, Onizuka, Makoto, additional, Watanabe, Kenichiro, additional, Takahashi, Yoshiyuki, additional, Hirakawa, Tsuneaki, additional, Nishio, Miwako, additional, Sakashita, Chizuko, additional, Kobayashi, Tohru, additional, Sawada, Akihisa, additional, Ichinohe, Tatsuo, additional, Fukuda, Takahiro, additional, Hashii, Yoshiko, additional, Atsuta, Yoshiko, additional, and Arai, Ayako, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results